Jagsonpal Pharmaceuticals Reports Q1 Unaudited Results; Announces Share Buyback Plan
Jagsonpal Pharmaceuticals Limited released its unaudited financial results for the quarter ended June 30, 2026. The company also announced a recommended dividend and provided details regarding an ongoing share acquisition.The Board of Directors reviewed the results alongside the Independent Auditor's Limited Review Report on Unaudited Quarterly Financial Results.
Q1 FY27 Performance Snapshot
The financial performance for the quarter ending June 30, 2026, showed specific figures across various metrics. The company continues its engagement in manufacturing and trading of pharmaceutical products to customers in India and overseas.Key financial data for Jagsonpal Pharmaceuticals Limited is presented below:
| Particulars | Quarter Ended 30 June 2026 (Unaudited) | Quarter Ended 31 March 2026 (Audited) | Quarter Ended 30 June 2025 (Unaudited) | Year Ended 31 March 2026 (Audited) |
|---|---|---|---|---|
| Revenue from operations | 822.32 | 642.03 | 756.12 | 2,872.25 |
| Total income (Operations + Other) | 850.65 | 673.71 | 784.37 | 2,992.20 |
| Total expenses | 673.85 | 556.15 | 640.06 | 2,396.23 |
| Net profit for the period | 131.89 | 87.62 | 107.95 | 430.82 |
| Total comprehensive income | 132.83 | 88.72 | 108.52 | 434.46 |
Corporate Decisions and Business Updates
In corporate actions related to the previous fiscal year, the Board of Directors recommended a final dividend of ₹4 per equity share (of face value ₹2) for the year ended March 31, 2026, pending approval at the Annual General Meeting.The company also undertook a buy-back of up to 1,600,000 equity shares of face value ₹2 each. This buy back was executed through the tender offer route and involved an aggregate consideration not exceeding ₹400 million.
In terms of strategic business development during the quarter, Jagsonpal Pharmaceuticals entered into a Share Purchase Agreement on June 29, 2026, to acquire an 85% equity stake in Aequitas Healthcare Private Limited. The total consideration for this acquisition was set at ₹208 million and is proposed to be funded through internal accruals.
The existing promoters and directors of Aequitas will retain a 15% shareholding and will continue to manage the business post-acquisition. While the Share Purchase Agreement was executed during the quarter, the transfer of shares and completion of formalities occurred subsequently in July 2026.
Additionally, the company granted 153,000 stock options under its Employee Stock Option Plan 2022 and allotted 473,220 equity shares upon the exercise of vested stock options by eligible employees.
JAGSNPHARM Stock Price Movement
Today, Jagsonpal Pharmaceuticals Limited shares edged higher, closing at ₹230.5 after gaining 2.20% against the previous close. The stock saw strong movement during trading, with a total volume of 77,095 shares recorded today.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.